Trial Profile
A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary P. Aeruginosa Requiring Frequent Antibiotics (AIR-CF2).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aztreonam (Primary)
- Indications Cystic fibrosis; Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Registrational; Therapeutic Use
- Acronyms AIR-CF2
- Sponsors Corus Pharma; Gilead Sciences
- 02 Aug 2007 New trial record.